Preliminary study on serum paraoxonase-1 status and chemokine (C-C motif) ligand 2 in hospitalized elderly patients with catheter-associated asymptomatic bacteriuria

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 35, Issue 9, 2016, Pages 1417-1424

  Iftimie, S ^a   Garcia Heredia A ^a   Pujol, I ^a   Ballester, F ^a   Fort Gallifa, I ^a   Simo J M ^a   Joven, J ^a   Camps, J ^a   Castro, A ^a  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; BIOLOGICAL MARKER; C REACTIVE PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PROCALCITONIN; CALCITONIN; CCL2 PROTEIN, HUMAN; PON1 PROTEIN, HUMAN;

ADULT; AGED; AGED HOSPITAL PATIENT; ARTICLE; ASYMPTOMATIC BACTERIURIA; BLOOD BIOCHEMISTRY; CATHETER INFECTION; CHARLSON COMORBIDITY INDEX; COLONY FORMING UNIT; COMORBIDITY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DNA POLYMORPHISM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FRAIL ELDERLY; GENOTYPE; HUMAN; INDWELLING URINARY CATHETER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; URINE CULTURE; ASYMPTOMATIC DISEASE; BACTERIURIA; BLOOD; CATHETER-RELATED INFECTIONS; CHEMISTRY; HOSPITALIZATION; MIDDLE AGED; PROSPECTIVE STUDY; SERUM; URINARY TRACT INFECTIONS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ARYLDIALKYLPHOSPHATASE; ASYMPTOMATIC DISEASES; BACTERIURIA; C-REACTIVE PROTEIN; CALCITONIN; CATHETER-RELATED INFECTIONS; CHEMOKINE CCL2; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SERUM; URINARY TRACT INFECTIONS;

EID: 84975527355     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-016-2679-8     Document Type: Article

References (38)

1. High KP, Bradley SF, Gravenstein S, Mehr DR, Quagliarello VJ, Richards C, Yoshikawa TT (2009) Clinical practice guideline for the evaluation of fever and infection in older adult residents of long-term care facilities: 2008 update by the infectious diseases society of America. Clin Infect Dis 48(2):149–171
2. Nicolle LE (2014) Catheter-related urinary tract infection: practical management in the elderly. Drugs Aging 31(1):1–10
3. Trautner BW (2010) Management of catheter-associated urinary tract infection. Curr Opin Infect Dis 23(1):76–82
4. Theodorou VP, Papaioannou VE, Tripsianis GA, Panopoulou MK, Christophoridis EK, Kouliatsis GA, Gioka TM, Maltezos ES, Ktenidou-Kartali SI, Pneumatikos IA (2012) Procalcitonin and procalcitonin kinetics for diagnosis and prognosis of intravascular catheter-related bloodstream infections in selected critically ill patients: a prospective observational study. BMC Infect Dis 12:247
5. Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM, Infectious Diseases Society of America; American Society of Nephrology; American Geriatric Society (2005) Infectious Diseases Society of America Guidelines for the diagnosis and treatment of symptomatic bacteriuria in adults. Clin Infect Dis 40(5):643–654
6. Zhanel GG, Harding GK, Guay DR (1990) Asymptomatic bacteriuria. Which patients should be treated. Arch Intern Med 150(7):1389–1396
7. Nicolle LE (2000) Asymptomatic bacteriuria in institutionalized elderly people; evidence and practice. CMAJ 163(3):285–286
8. Henriquez-Camacho C, Losa J (2014) Biomarkers for sepsis. Biomed Res Int 2014:547818
9. Iftimie S, García-Heredia A, Pujol I, Ballester F, Fort-Gallifa I, Simó JM, Joven J, Castro A, Camps J (2015) A preliminary study of paraoxonase-1 in infected patients with an indwelling central venous catheter. Clin Biochem 49(6):449–457. doi:10.1016/j.clinbiochem.2015.11.006
10. Camps J, Marsillach J, Joven J (2009) The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci 46(2):83–106
11. Mete R, Oran M, Alpsoy S, Gunes H, Tulubas F, Turan C, Topcu B, Aydin M, Yildirim O (2013) Carotid intima-media thickness and serum paraoxonase-1 activity in patients with Helicobacter pylori. Eur Rev Med Pharmacol Sci 17(21):2884–2889
12. Parra S, Marsillach J, Aragonés G, Beltrán R, Montero M, Coll B, Mackness B, Mackness M, Alonso-Villaverde C, Joven J, Camps J (2010) Paraoxonase-1 gene haplotypes are associated with metabolic disturbances, atherosclerosis, and immunologic outcome in HIV-infected patients. J Infect Dis 201(4):627–634
13. Richter RJ, Jarvik GP, Furlong CE (2010) Paraoxonase 1 status as a risk factor for disease or exposure. Adv Exp Med Biol 660:29–35
14. McCabe WR, Jackson GG (1962) Gram-negative bacteremia. I. Etiology and ecology. Arch Intern Med 110:847–864
15. Berkman LF, Leo-Summers L, Horwitz RI (1992) Emotional support and survival after myocardial infarction. A prospective, population-based study of the elderly. Ann Intern Med 117(12):1003–1009
16. Ferré N, Camps J, Fernández-Ballart J, Arija V, Murphy MM, Ceruelo S, Biarnés E, Vilella E, Tous M, Joven J (2003) Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin Chem 49(9):1491–1497
17. Marsillach J, Aragonès G, Beltrán R, Caballeria J, Pedro-Botet J, Morcillo-Suárez C, Navarro A, Joven J, Camps J (2009) The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment. Clin Biochem 42(1–2):91–98
18. Martinelli N, Garcia-Heredia A, Roca H, Aranda N, Arija V, Mackness B, Busti F, Aragonès G, Pedro-Botet J, Pedica F, Cataldo I, Marsillach J, Joven J, Girelli D, Camps J (2013) Paraoxonase-1 status in patients with hereditary hemochromatosis. J Lipid Res 54(5):1484–1492
19. Andreu A, Cacho J, Coira A, Lepe JA (2011) Diagnóstico microbiológico de las infecciones del tracto urinario. Enferm Infecc Microbiol Clin 29:52–57
20. Zweig MH, Campbell G (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39(4):561–577
21. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, Newton RS, La Du B (1999) Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Rad Biol Med 26(7–8):892–904
22. Camps J, Mackness M, Mackness B, Marsillach J, Joven J (2010) Serum paraoxonase-1 activity and genetic polymorphisms: common errors in measurement and interpretation of results. Clin Chem Lab Med 48(6):893–894
23. Camps J, Rodríguez-Gallego E, García-Heredia A, Triguero I, Riera-Borrull M, Hernández-Aguilera A, Luciano-Mateo F, Fernández-Arroyo S, Joven J (2014) Paraoxonases and chemokine (C-C motif) ligand-2 in noncommunicable diseases. Adv Clin Chem 63:247–308
24. Charo IF, Taubman MB (2004) Chemokines in the pathogenesis of vascular disease. Circ Res 95(9):858–866
25. Mackness B, Hine D, Liu Y, Mastorikou M, Mackness M (2004) Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun 318(3):680–683
26. Rodríguez-Sanabria F, Rull A, Beltrán-Debón R, Aragonès G, Camps J, Mackness B, Mackness M, Joven J (2010) Tissue distribution and expression of paraoxonases and chemokines in mouse: the ubiquitous and joint localisations suggest a systemic and coordinated role. J Mol Histol 41(6):379–386
27. Rull A, Camps J, Alonso-Villaverde C, Joven J (2010) Insulin resistance, inflammation, and obesity: role of monocyte chemoattractant protein-1 (or CCL2) in the regulation of metabolism. Mediators Inflamm
28. Petrkova J, Szotkowska J, Hermanova Z, Lukl J, Petrek M (2004) Monocyte chemoattractant protein-1 in patients with peripheral arterial disease. Mediat Inflamm 13(1):39–43
29. Sans T, Rull A, Luna J, Mackness B, Mackness M, Joven J, Ibañez M, Pariente R, Rodriguez M, Ortin X, Masdeu G, Camps J (2012) Monocyte chemoattractant protein-1 and paraoxonase-1 and 3 levels in patients with sepsis treated in an intensive care unit: a preliminary report. Clin Chem Lab Med 50(8):1409–1415
30. Ramanathan R, Duane TM (2014) Urinary tract infections in surgical patients. Surg Clin Borth Am 94(6):1351–1368
31. Becknell B, Schober M, Korbel L, Spencer JD (2015) The diagnosis, evaluation and treatment of acute and recurrent pediatric urinary tract infections. Expert Rev Anti Infect Ther 13(1):81–90
32. Khasriya R, Khan S, Lunawat R, Bishara S, Bignall J, Malone-Lee M, Ishii H, O’Connor D, Kelsey M, Malone-Lee J (2010) The inadequacy of urinary dipstick and microscopy as surrogate markers of urinary tract infection in urological outpatients with lower urinary tract symptoms without acute frequency and dysuria. J Urol 183(5):1843–1847
33. Wang H, Yin F, Shen DX, Zhang YJ, Luo YP, Liu CJ, Wang KF, Zhou G, Ye LY, Chen G, Wang XN (2013) Predictive value of procalcitonin for excluding bloodstream infection: results of a retrospective study and utility of a rapid, quantitative test for procalcitonin. J Int Med Res 41(5):1671–1681
34. st century. BJU Int 109(12):1746–1749
35. Camps J, Pujol I, Ballester F, Joven J, Simó JM (2011) Paraoxonases as potential antibiofilm agents: their relationship with quorum-sensing signals in Gram-negative bacteria. Antimicrob Agents Chemother 55(4):1325–1331
36. Liu YC, Chan KG, Chang CY (2015) Modulation of host biology by Pseudomonas aeruginosa quorum sensing signal molecules: Messengers or traitors. Front Microbiol 6:1226
37. Ozer EA, Pezzulo A, Shih DM, Chun C, Furlong C, Lusis AJ, Greenberg EP, Zabner J (2005) Human and murine paraoxonase 1 are host modulators of Pseudomonas aeruginosa quorum sensing. FEMS Microbiol Lett 253(1):29–37
38. Schweikert EM, Amort J, Wilgenbus P, Förstermann U, Teiber JF, Horke S (2012) Paraoxonases-2 and −3 are important defense enzymes against Pseudomonas aeruginosa virulence factors due to their anti-oxidative and anti-inflammatory properties. J Lipids 2012:352857